Literature DB >> 18623111

Endothelin-1 enhances the expression of the androgen receptor via activation of the c-myc pathway in prostate cancer cells.

June G Lee1, Rong Zheng, Jennifer M McCafferty-Cepero, Kerry L Burnstein, David M Nanus, Ruoqian Shen.   

Abstract

Increasing evidence suggests that androgen independent prostate cancer (PC) maintains a functional androgen receptor (AR) pathway despite the low levels of circulating androgen following androgen withdrawal, the molecular mechanisms of which are not well defined yet. To address this question, we investigated the effects of endothelin-1 (ET-1) on AR expression. Western analysis and RT-PCR revealed that in the presence of ET-1, levels of AR significantly increased in a time- and dose-dependent manner in LNCaP cells. Pretreatments with inhibitors of Src and phosphoinositide kinase 3 (PI-3K) suppressed ET-1-induced AR expression. As ET-1 was reported to cause a transient increase in c-myc mRNA levels, we examined the involvement of c-myc in ET-1-mediated AR expression. Transient transfection of c-myc siRNA neutralized ET-1-induced AR expression, suggesting that AR induction by ET-1 is c-myc dependent. AR can regulate the transcription of its own gene via a mechanism in which c-myc plays a crucial role. Therefore, we assessed if ET-1-induced-c-myc leads to the enhancement of AR transcription. Reporter gene assays using the previously identified AR gene enhancer containing a c-myc binding site were conducted in LNCaP cells. We found that ET-1 induced reporter gene activity from the construct containing the wild-type but not mutant c-myc binding site. Chromatin immunoprecipitation assays confirmed that ET-1 increased interaction between c-myc and c-myc binding sites in AR enhancer, suggesting that ET-1-induced AR transcription occurs via c-myc-mediated AR transcription. Together, these data support the notion that ET-1, via Src/PI-3K signaling, augments c-myc expression leading to enhanced AR expression in PC. Copyright 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18623111      PMCID: PMC4280021          DOI: 10.1002/mc.20462

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  31 in total

1.  Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells.

Authors:  J Gong; J Zhu; O B Goodman; R G Pestell; P N Schlegel; D M Nanus; R Shen
Journal:  Oncogene       Date:  2006-03-30       Impact factor: 9.867

2.  Neutral endopeptidase inhibits neuropeptide-mediated transactivation of the insulin-like growth factor receptor-Akt cell survival pathway.

Authors:  M Sumitomo; M I Milowsky; R Shen; D Navarro; J Dai; T Asano; M Hayakawa; D M Nanus
Journal:  Cancer Res       Date:  2001-04-15       Impact factor: 12.701

3.  Elevated serum chromogranin A is detectable in patients with carcinomas at advanced disease stages.

Authors:  J T Wu; A J Erickson; K C Tsao; T L Wu; C F Sun
Journal:  Ann Clin Lab Sci       Date:  2000-04       Impact factor: 1.256

4.  Evidence for Somatostatin receptor 2 in thyroid tissue.

Authors:  M Druckenthaner; C Schwarzer; C Ensinger; M Gabriel; R Prommegger; G Riccabona; C Decristoforo
Journal:  Regul Pept       Date:  2006-09-20

5.  Neutral endopeptidase promotes phorbol ester-induced apoptosis in prostate cancer cells by inhibiting neuropeptide-induced protein kinase C delta degradation.

Authors:  M Sumitomo; R Shen; J S Goldberg; J Dai; D Navarro; D M Nanus
Journal:  Cancer Res       Date:  2000-12-01       Impact factor: 12.701

Review 6.  Expression and function of androgen receptor in carcinoma of the prostate.

Authors:  Z Culig; A Hobisch; G Bartsch; H Klocker
Journal:  Microsc Res Tech       Date:  2000-12-01       Impact factor: 2.769

7.  Localization of endothelin receptors in the human prostate.

Authors:  S Kobayashi; R Tang; B Wang; T Opgenorth; E Stein; E Shapiro; H Lepor
Journal:  J Urol       Date:  1994-03       Impact factor: 7.450

8.  Prolactin induces c-Myc expression and cell survival through activation of Src/Akt pathway in lymphoid cells.

Authors:  María Aurora Domínguez-Cáceres; José Manuel García-Martínez; Annarica Calcabrini; Lorena González; Pedro González Porque; Javier León; Jorge Martín-Pérez
Journal:  Oncogene       Date:  2004-09-23       Impact factor: 9.867

9.  In vivo amplification of the androgen receptor gene and progression of human prostate cancer.

Authors:  T Visakorpi; E Hyytinen; P Koivisto; M Tanner; R Keinänen; C Palmberg; A Palotie; T Tammela; J Isola; O P Kallioniemi
Journal:  Nat Genet       Date:  1995-04       Impact factor: 38.330

10.  Bombesin attenuates pre-mRNA splicing of glucocorticoid receptor by regulating the expression of serine-arginine protein p30c (SRp30c) in prostate cancer cells.

Authors:  Jin Zhu; Jun Y Gong; Oscar B Goodman; Luca Cartegni; David M Nanus; Ruoqian Shen
Journal:  Biochim Biophys Acta       Date:  2007-05-03
View more
  10 in total

Review 1.  Gene expression profiles of NO- and HNO-donor treated breast cancer cells: insights into tumor response and resistance pathways.

Authors:  Robert Y S Cheng; Debashree Basudhar; Lisa A Ridnour; Julie L Heinecke; Aparna H Kesarwala; Sharon Glynn; Christopher H Switzer; Stefan Ambs; Katrina M Miranda; David A Wink
Journal:  Nitric Oxide       Date:  2014-08-19       Impact factor: 4.427

2.  A genome-wide association study of severe teenage acne in European Americans.

Authors:  Mingfeng Zhang; Abrar A Qureshi; David J Hunter; Jiali Han
Journal:  Hum Genet       Date:  2013-10-11       Impact factor: 4.132

Review 3.  Targeting the endothelin axis in prostate carcinoma.

Authors:  Alvaro Pinto; María Merino; Pilar Zamora; Andrés Redondo; Beatriz Castelo; Enrique Espinosa
Journal:  Tumour Biol       Date:  2011-12-29

4.  Dynamics of plasma proteome during leptin-replacement therapy in genetically based leptin deficiency.

Authors:  V P Andreev; R C Dwivedi; G Paz-Filho; O V Krokhin; M-L Wong; J A Wilkins; J Licinio
Journal:  Pharmacogenomics J       Date:  2010-05-11       Impact factor: 3.245

5.  Expression and functional role of orphan receptor GPR158 in prostate cancer growth and progression.

Authors:  Nitin Patel; Tatsuo Itakura; Shinwu Jeong; Chun-Peng Liao; Pradip Roy-Burman; Ebrahim Zandi; Susan Groshen; Jacek Pinski; Gerhard A Coetzee; Mitchell E Gross; M Elizabeth Fini
Journal:  PLoS One       Date:  2015-02-18       Impact factor: 3.240

6.  IKBKE activity enhances AR levels in advanced prostate cancer via modulation of the Hippo pathway.

Authors:  Alex Bainbridge; Scott Walker; Joseph Smith; Kathryn Patterson; Aparna Dutt; Yi Min Ng; Huw D Thomas; Laura Wilson; Benjamin McCullough; Dominic Jones; Arussa Maan; Peter Banks; Stuart R McCracken; Luke Gaughan; Craig N Robson; Kelly Coffey
Journal:  Nucleic Acids Res       Date:  2020-06-04       Impact factor: 16.971

7.  RNF8 up-regulates AR/ARV7 action to contribute to advanced prostate cancer progression.

Authors:  Tingting Zhou; Shengli Wang; Xiaoyu Song; Wensu Liu; Fang Dong; Yunlong Huo; Renlong Zou; Chunyu Wang; Siyi Zhang; Wei Liu; Ge Sun; Lin Lin; Kai Zeng; Xiang Dong; Qiqiang Guo; Fei Yi; Zhuo Wang; Xiaoman Li; Bo Jiang; Liu Cao; Yue Zhao
Journal:  Cell Death Dis       Date:  2022-04-15       Impact factor: 9.685

8.  Reciprocal regulation of CIP2A and AR expression in prostate cancer cells.

Authors:  Hao-Wen Chuang; Jian-Hua Pan; Yi-Xuan Cai; Darius Rupa; Ting-Syuan Huang; Tzu-Chien Kuo; Chiao-Wen Lin; Chi-Wei Chen; Chia-Chin Lin; Herng-Sheng Lee; Ta-Chun Yuan
Journal:  Discov Oncol       Date:  2022-09-13

9.  Regulation of several androgen-induced genes through the repression of the miR-99a/let-7c/miR-125b-2 miRNA cluster in prostate cancer cells.

Authors:  D Sun; R Layer; A C Mueller; M A Cichewicz; M Negishi; B M Paschal; A Dutta
Journal:  Oncogene       Date:  2013-03-18       Impact factor: 9.867

10.  Endothelin-1 induces changes in the expression levels of steroidogenic enzymes and increases androgen receptor and testosterone production in the PC3 prostate cancer cell line.

Authors:  María José Torres; Fernanda López-Moncada; Daniela Herrera; Sebastián Indo; Alejandro Lefian; Paola Llanos; Julio Tapia; Enrique A Castellón; Héctor R Contreras
Journal:  Oncol Rep       Date:  2021-06-24       Impact factor: 3.906

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.